ImmunoGen, Inc. (IMGN) — Financial statements
Income statement, balance sheet, and cash flow for ImmunoGen, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 109↑55.7% | 70↓47.2% | 132↑60.8% | 82↑52.9% | 54 | |
| Cost of Revenue | 0.18 | 0.00↓100.0% | 115↑0.1% | 115↓34.1% | 174 | |
| Gross Profit | 109↑55.5% | 70↑294.5% | 18↑154.9% | -32↑73.1% | -120 | |
| Operating Expenses | ||||||
| R&D Expenses | 213↑41.2% | 151↑31.9% | 115↑0.1% | 115↓34.1% | 174 | |
| General & Administrative Expenses | 0.00↓100.0% | 44↑13.5% | 39↑0.3% | 38↑4.8% | 37 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 116↑165.1% | 44↑13.5% | 39↑0.3% | 38↑4.8% | 37 | |
| Other Expenses | -0.99↑12.1% | -1↓193.5% | 1↓75.9% | 5↑50.5% | 3 | |
| Operating Expenses | 329↑69.0% | 195↑27.2% | 153↑0.1% | 153↓27.3% | 211 | |
| Total Costs & Expenses | 330↑69.1% | 195↑27.2% | 153↑0.1% | 153↓27.3% | 211 | |
| Operating Results | ||||||
| Operating Income | -221↓76.6% | -125↑7.7% | -135↓47.0% | -92↑42.6% | -160 | |
| Depreciation & Amortization | 2↓11.6% | 2↓98.3% | 116↑337.9% | 26↑256.9% | 7 | |
| EBITDA | -216↓73.7% | -124↓530.9% | -20↑70.1% | -66↑57.2% | -153 | |
| EBIT | -218↓61.0% | -135↓24896.0% | 0.55↑100.6% | -87↑41.9% | -150 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.18↑104.3% | -4↑81.7% | -22↓79.1% | -13↓17.0% | -11 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.73↓83.5% | 4 | 0.00 | |
| Interest Expense | 4↓68.3% | 13↓43.3% | 23↑36.7% | 17↑58.3% | 11 | |
| Non-Operating Income | -3↓133.3% | 10↑143.9% | -23↓357.2% | -5↑51.6% | -10 | |
| Other Income / Expenses | 3↑409.9% | -1↑95.1% | -22↓83.9% | -12↓43.0% | -8 | |
| Income Before Tax | -222↓59.2% | -139↓213.9% | -44↑57.4% | -104↑38.0% | -168 | |
| Income Tax Expense | 1 | 0.00↓100.0% | 22↑24.2% | 18 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -223↑0.0% | -223↓234.3% | -67↑45.4% | -122↑27.3% | -168 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -223↓60.0% | -139↓108.9% | -67↑45.4% | -122↑27.3% | -168 | |
| Bottom-Line Net Income | -223↑0.0% | -223↓234.3% | -67↑45.4% | -122↑27.3% | -168 | |
| EPS (Basic) | -0.88↑18.7% | -1.08↓184.6% | -0.38↑53.7% | -0.82↑31.7% | -1.20 | |
| EPS (Diluted) | -0.88↑18.7% | -1.08↓184.6% | -0.38↑53.7% | -0.82↑31.7% | -1.20 | |
| Weighted Average Shares | 254↑23.0% | 206↑17.0% | 176↑18.8% | 148↑6.0% | 140 | |
| Weighted Average Diluted Shares | 254↑23.0% | 206↑17.0% | 176↑18.8% | 148↑6.0% | 140 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.